Dennis Langer Biography and Net Worth

Director of Quoin Pharmaceuticals

Dr. Langer has served as a director of Quoin Inc. since 2019 and as a director of Quoin Ltd. since October 28, 2021. After graduating from Georgetown School of Medicine and Harvard Law School, Dr. Langer spent over 35 years in the pharmaceutical industry at Eli Lilly, Abbott, Searle, GSK and as President at Dr. Reddy’s Pharmaceuticals. He has also served as Chief Executive Officer at Neose Technologies, Inc. Dr. Langer has served as director at a number of companies including Sirna Therapeutics (acquired by Merck), Ception Therapeutics (acquired by Cephalon), Transkaryotic Therapies (acquired by Shire), Pharmacopeia (acquired by Ligand), Cytogen (acquired by EUSA Pharma), Brooklyn ImmunoTherapeutics, Inc. and Delcath Systems. Dr. Langer is currently a Director at Myriad Genetics, Dicerna Pharmaceuticals and Pernix Therapeutics. He is a Clinical Psychiatry Professor at Georgetown and serves on the Dean’s Advisory Board of Harvard Law School. He received an M.D. from Georgetown University School of Medicine, a J.D. from Harvard Law School, and a B.A. in Biology from Columbia University.

What is Dennis Langer's net worth?: The estimated net worth of Dennis Langer is at least $71.52 thousand as of October 14th, 2025. Dr. Langer owns 15,153 shares of Quoin Pharmaceuticals stock worth more than $71,522 as of October 7th. This net worth estimate does not reflect any other assets that Dr. Langer may own. Learn More about Dennis Langer's net worth.
How do I contact Dennis Langer?: The corporate mailing address for Dr. Langer and other Quoin Pharmaceuticals executives is 23 Hata'as Street, Kfar Saba, 44425. Quoin Pharmaceuticals can also be reached via phone at +97299741444 and via email at [email protected]. Learn More on Dennis Langer's contact information.
Has Dennis Langer been buying or selling shares of Quoin Pharmaceuticals?: Dennis Langer has not been actively trading shares of Quoin Pharmaceuticals during the last quarter. Most recently, on Tuesday, October 14th, Dennis Langer bought 15,152 shares of Quoin Pharmaceuticals stock. The stock was acquired at an average cost of $8.49 per share, with a total value of $128,640.48. Following the completion of the transaction, the director now directly owns 15,153 shares of the company's stock, valued at $128,648.97. Learn More on Dennis Langer's trading history.
Who are Quoin Pharmaceuticals' active insiders?: Quoin Pharmaceuticals' insider roster includes Denise Carter (COO), Anthony Culverwell (Director), and Dennis Langer (Director). Learn More on Quoin Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Quoin Pharmaceuticals?: In the last twelve months, Quoin Pharmaceuticals insiders bought shares 5 times. They purchased a total of 72,522 shares worth more than $408,606.08. The most recent insider tranaction occured on August, 31st when COO Denise P. Carter bought 20,490 shares worth more than $99,991.20. Insiders at Quoin Pharmaceuticals own 11.2% of the company. Learn More about insider trades at Quoin Pharmaceuticals.
Information on this page was last updated on 8/31/2026.

Dennis Langer Insider Trading History at Quoin Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/14/2025	Buy	15,152	$8.49	$128,640.48	15,153
6/7/2024	Sell	8	$25.55	$204.40	1

Dennis Langer Buying and Selling Activity at Quoin Pharmaceuticals

Quoin Pharmaceuticals Company Overview

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Today's Range

Now: $4.62

$4.51

$4.79

50 Day Range

MA: $5.73

$4.26

$7.87

2 Week Range

Now: $4.62

$3.25

$41.80

Volume

3,610 shs

Average Volume

292,420 shs

Market Capitalization

$9.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56